caa a22 4500 469074396 CHVBK 20180323132931.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF01741550 doi (NATIONALLICENCE)springer-10.1007/BF01741550 The CySF-L2 factor from dialysable human leucocyte extract activates natural killer cytotoxicity by induction of interferon γ [Elektronische Daten] [Ingeborg Doelker, F. Anderer] Summary: The mechanism of natural killer (NK) cytotoxicity activation of human peripheral blood mononuclear cells (PBMC) by CySF-L2 was elucidated. CySF-L2 is a cytotoxicity-stimulating factor isolated from dialysable human leucocyte extract, which activates NK cytotoxicity against NK-sensitive and insensitive tumour cells (K562; Daudi; Raji; MOLT4) when preincubated with effector cells for 72 h. CySF-L2-mediated activation was synergistic to interleukin-2(IL-2)-mediated activation of NK cytotoxicity. Induction of interferon γ (IFNγ) release was the crucial step during CySF-L2-mediated NK cytotoxicity activation since enhancement of NK activity was completely blocked when anti-IFNγ antibodies were present during treatment of PBMC. Anti-IFNα, anti-TNFα (tumour necrosis factor α) anti-IL-1 and anti-IL-2 antibodies showed no blocking effect. Analysis of the supernatant culture medium after 72 h incubation of PBMC and their highly purified subpopulations demonstrated that CySF-L2 induced release of IFNγ from CD3+T cells and CD56+CD3− NK cells and of TNFα and prostaglandin E2 from monocytes. CySF-L2 was also capable of activating NK cytotoxicity of highly purified (98%) CD56+CD3− NK cells as well as of monocytes (94% pure). Cell cooperation studies connected with analysis of cytokine release and enhancement of NK cytotoxicity indicated that CySF-L2 might play an essential role in the up and down regulation of NK cytotoxicity by the cytokine network. Springer-Verlag, 1992 NK cytotoxicity nationallicence Cytotoxicity-stimulating factor nationallicence Cytokine network nationallicence Antitumour activity nationallicence Doelker Ingeborg Friedrich-Miescher-Laboratorium, Max-Planck-Gesellschaft, Spemannstrasse 37/39, D-7400, Tübingen, Germany aut Anderer F. Friedrich-Miescher-Laboratorium, Max-Planck-Gesellschaft, Spemannstrasse 37/39, D-7400, Tübingen, Germany aut Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 299-305 0340-7004 34:5<299 1992 34 262 https://doi.org/10.1007/BF01741550 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741550 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Doelker Ingeborg Friedrich-Miescher-Laboratorium, Max-Planck-Gesellschaft, Spemannstrasse 37/39, D-7400, Tübingen, Germany aut NATIONALLICENCE 700 1- Anderer F. Friedrich-Miescher-Laboratorium, Max-Planck-Gesellschaft, Spemannstrasse 37/39, D-7400, Tübingen, Germany aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 299-305 0340-7004 34:5<299 1992 34 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer